Haloperidol
- PMID: 32809727
- Bookshelf ID: NBK560892
Haloperidol
Excerpt
Haloperidol, a first-generation typical antipsychotic, is commonly used worldwide to block dopamine D2 receptors in the brain and exert its antipsychotic action. The medication is used to manage the positive symptoms of schizophrenia, including hallucinations and delusions. Haloperidol has received approval from the U.S. Food and Drug Administration (FDA) for a wide array of clinical applications, while also exhibiting off-label uses. The FDA-approved indications for haloperidol include schizophrenia, Tourette syndrome, and severe behavioral disorders in children, characterized by combative and explosive hyperexcitability, as well as hyperactivity in children, characterized by impulsivity, attention difficulties, aggressiveness, mood fluctuations, and low frustration tolerance. This activity highlights the mechanism of action, administration, adverse event profile, toxicity, monitoring, and pertinent interactions relevant to interprofessional healthcare team members when using haloperidol effectively to manage diverse indications.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
References
-
- López-Muñoz F, Alamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Res Bull. 2009 Apr 29;79(2):130-41. - PubMed
-
- McDonagh MS, Dana T, Selph S, Devine EB, Cantor A, Bougatsos C, Blazina I, Grusing S, Fu R, Kopelovich SL, Monroe-DeVita M, Haupt DW. Treatments for Schizophrenia in Adults: A Systematic Review [Internet] Agency for Healthcare Research and Quality (US); Rockville (MD): 2017. Oct, - PubMed
-
- Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, Servis M, Walaszek A, Buckley P, Lenzenweger MF, Young AS, Degenhardt A, Hong SH, (Systematic Review) The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry. 2020 Sep 01;177(9):868-872. - PubMed
-
- Kishi T, Ikuta T, Sakuma K, Okuya M, Iwata N. Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan. J Psychiatr Res. 2021 Jun;138:444-452. - PubMed
-
- Besag FM, Vasey MJ, Lao KS, Chowdhury U, Stern JS. Pharmacological treatment for Tourette syndrome in children and adults: What is the quality of the evidence? A systematic review. J Psychopharmacol. 2021 Sep;35(9):1037-1061. - PubMed
Publication types
LinkOut - more resources
Full Text Sources